A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01231919

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:42.720543+00:00

Published At

2014-04-29T00:00:00+00:00

Record Updated At

2014-04-29

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Accelerated Phase Chronic Myelogenous Leukemia", "Acute Leukemias of Ambiguous Lineage", "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder", "Acute Undifferentiated Leukemia", "Aggressive NK-cell Leukemia", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Intraocular Lymphoma", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Myeloid/NK-cell Acute Leukemia", "Noncutaneous Extranodal Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenstr\u00f6m Macroglobulinemia"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2014-04-29"

protocolSection.identificationModule.nctId

"NCT01231919"

protocolSection.identificationModule.officialTitle

"A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Accelerated Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Acute Leukemias of Ambiguous Lineage (protocolSection.conditionsModule.conditions)
• Acute Myeloid Leukemia/Transient Myeloproliferative Disorder (protocolSection.conditionsModule.conditions)
• Acute Undifferentiated Leukemia (protocolSection.conditionsModule.conditions)
• Aggressive NK-cell Leukemia (protocolSection.conditionsModule.conditions)
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (protocolSection.conditionsModule.conditions)
• Blastic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
• Childhood Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Childhood Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Childhood Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Childhood Grade III Lymphomatoid Granulomatosis (protocolSection.conditionsModule.conditions)
• Childhood Immunoblastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Childhood Nasal Type Extranodal NK/T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Chronic Eosinophilic Leukemia (protocolSection.conditionsModule.conditions)
• Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
• Chronic Neutrophilic Leukemia (protocolSection.conditionsModule.conditions)
• Chronic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Intraocular Lymphoma (protocolSection.conditionsModule.conditions)
• Juvenile Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
• Mast Cell Leukemia (protocolSection.conditionsModule.conditions)
• Myeloid/NK-cell Acute Leukemia (protocolSection.conditionsModule.conditions)
• Noncutaneous Extranodal Lymphoma (protocolSection.conditionsModule.conditions)
• Post-transplant Lymphoproliferative Disorder (protocolSection.conditionsModule.conditions)
• Primary Central Nervous System Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Primary Central Nervous System Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Progressive Hairy Cell Leukemia, Initial Treatment (protocolSection.conditionsModule.conditions)
• Prolymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Grade III Lymphomatoid Granulomatosis (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Small Noncleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 3 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
• Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent/Refractory Childhood Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
• Relapsing Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Secondary Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Small Intestine Lymphoma (protocolSection.conditionsModule.conditions)
• Splenic Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Unspecified Childhood Solid Tumor, Protocol Specific (protocolSection.conditionsModule.conditions)
• Waldenström Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.